Riskpilot← Back to searchSign inGet full accessBIO-CONVERT A/S
A/SActiveCVR 39842319Vandtårnsvej 62A, 1. bManufacture of pharmaceutical preparations · NACE 2120Est. 2018— employeeswww.bio-convert.com
Revenue 2025
DKK -93K
-85% vs 2024
EBITDA margin
100.0%
+85% vs 2024
Equity ratio
39.6%
Financial strength
Net profit 2025
DKK -99K
+84% vs 2024
| Revenue | DKK -93K | -85% |
| EBITDA | DKK -93K | +85% |
| Net profit | DKK -99K | +84% |
| Total assets | DKK 3,5M | +65% |
| Equity | DKK 1,4M | -7% |
| Employees | — | — |
Legal name
BIO-CONVERT A/S
CVR number
39842319
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
24. august 2018
Share capital
DKK 596.390
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren i forening med bestyrelsesformanden eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at udvikle repocitionerede lægemidler samt dermed beslægtet virksomhed.
Address
Vandtårnsvej 62A, 1. b
Phone
+4542901733
Email
info@bio-convert.com
Website
www.bio-convert.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -233 | 143 | -3 | -15 | -18 | -619 | -93 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -233 | 143 | -3 | -15 | -18 | -619 | -93 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -12 | -3 |
| EBIT | -233 | 143 | -3 | -15 | -18 | -631 | -96 |
| Net financials | -0 | -1 | -0 | 0 | -0 | -3 | -3 |
| Profit before tax | -233 | 142 | -3 | -15 | -19 | -635 | -99 |
| Tax | -51 | 33 | 21 | -0 | -0 | -0 | -0 |
| Net profit | -182 | 109 | -24 | -15 | -19 | -635 | -99 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 121 | 249 | 215 | 0 | 450 | 2.141 | 3.524 |
| Equity | -132 | -23 | -47 | -62 | 319 | 1.494 | 1.395 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 253 | 272 | 262 | 62 | 130 | 647 | 2.129 |
| Total debt | 253 | 272 | 262 | 62 | 130 | 647 | 2.129 |
EBITDA margin
-9291300.0%
This company
15.8%
Market median
-58805796% vs market
20192025
Equity ratio
39.6%
This company
38.2%
Market median
+4% vs market
20192025
Return on equity
-7.1%
This company
18.4%
Market median
-139% vs market
20192025
Net profit margin
-9892700.0%
This company
8.1%
Market median
-122132199% vs market
20192025
Asset turnover
-0.03×
This company
1.12×
Market median
-103% vs market
20192025
Debt / equity
1.53×
This company
0.62×
Market median
-147% vs market
20192025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-08-24 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TG Management | Management | 2023 | — | — |
NC Management | Management | 2018 | — | — |
AT Management | Management | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2024 | |
ABCHill Holding ApS | Company | 5.0% | 5.0% | 2024 |
Alteral Therapeutics ApS | Company | 33.3% | 33.3% | 2023 |
GK PARTNERS ApS | Company | 5.0% | 5.0% | 2024 |
| Individual | 100.0% | 100.0% | 2018 | |
AC Nordic ApS | Company | 25.0% | 25.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIO-CONVERT A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tom Glæsner Larsen | Management | 0 companies |
| Nelli Carla Gotfredsen | Management | 0 companies |
| Allan Traugott Wehnert | Management | 0 companies |
| Samia Sofie Kappe | Board of Directors | 0 companies |
| Christian Torben Hill-Madsen | Board of Directors | 0 companies |
| Peter Severin Bach | Chairman | 0 companies |
| Henrik Rouf | Board of Directors | 0 companies |
| Henrik Keller | Board of Directors | 0 companies |